First-in-man application of a novel therapeutic cancer vaccine formulation with the capacity to induce multi-functional T cell responses in ovarian, breast and prostate cancer patients

BACKGROUND: DepoVax(TM) is a novel non-emulsion depot-forming vaccine platform with the capacity to significantly enhance the immunogenicity of peptide cancer antigens. Naturally processed HLA-A2 restricted peptides presented by breast, ovarian and prostate cancer cells were used as antigens to crea...

Descripción completa

Detalles Bibliográficos
Autores principales: Berinstein, Neil L, Karkada, Mohan, Morse, Michael A, Nemunaitis, John J, Chatta, Gurkamal, Kaufman, Howard, Odunsi, Kunle, Nigam, Rita, Sammatur, Leeladhar, MacDonald, Lisa D, Weir, Genevieve M, Stanford, Marianne M, Mansour, Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479010/
https://www.ncbi.nlm.nih.gov/pubmed/22862954
http://dx.doi.org/10.1186/1479-5876-10-156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3479010/
https://www.ncbi.nlm.nih.gov/pubmed/22862954
http://dx.doi.org/10.1186/1479-5876-10-156

Ejemplares similares